Genetic Counseling

TOP - Daily published on June 15, 2011 in Breast Cancer, Genetic Counseling

The US Food and Drug Administration (FDA) has approved Inform Dual ISH (Ventana Medical Systems), a genetic test that allows for measurement of the number of copies of the HER2 gene in tumor tissue. This method of identification of women with breast cancer who are HER2-positive pinpoints who is, and who is not, a candidate for Herceptin (trastuzumab).

 


Results 1 - 1 of 1